BioCentury | Aug 1, 2008
Financial News

Sierra raises $21.5M

...raised $21.5 million in a series A round co-led by HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners...
BioCentury | Sep 27, 2007
Financial News

GlobeImmune raises $41.2 million

...Boston Life Science Venture Corp.; and WRF Capital joined existing investors HealthCare Ventures; Morgenthaler Ventures; Sequel Venture Partners...
BioCentury | Sep 19, 2005
Finance

Ebb & Flow

...round were Duquesne; Healthcare Investment Partners; MDS Capital; HealthCare Ventures; TPG Ventures; Morgenthaler Ventures; Perseus; Sequel Venture Partners...
BioCentury | Sep 15, 2005
Financial News

GlobeImmune raises $34.3 million

...Genentech (DNA); Partners Healthcare; and GC&H Investments joined existing investors HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners...
BioCentury | Sep 9, 2005
Financial News

Replidyne raises $62.5 million

...Healthcare Investment Partners; and MDS Capital. Existing investors HealthCare Ventures; TPG Ventures; Morgenthaler Ventures; Perseus; Sequel Venture Partners...
BioCentury | Oct 4, 2004
Finance

4Q Financial Markets Preview: Room to maneuver

...at $6.53. Investors included existing stockholders New Enterprise Associates; InterWest Partners; Perseus-Soros Biopharmaceutical Fund; and Sequel Venture Partners...
BioCentury | Sep 27, 2004
Financial News

Myogen raises $60 million

...1.8 million shares at $7.80 each. Investors included New Enterprise Associates; InterWest Partners; Perseus-Soros; and Sequel Venture Partners...
BioCentury | Aug 23, 2004
Finance

Follow the money

...TPG Ventures led the round. Other investors included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Morgenthaler; and Sequel Venture Partners...
BioCentury | Aug 17, 2004
Financial News

Replidyne raises $40 million

...investors in the infectious disease company included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners...
BioCentury | Sep 1, 2003
Finance

Ebb & Flow

...stockholders include New Enterprise Associates (28.5%); JPMorgan (20.4%); InterWest (13%); Perseus-Soros BioPharmaceutical Fund (8.1%); and Sequel Venture Partners...
Items per page:
1 - 10 of 13
BioCentury | Aug 1, 2008
Financial News

Sierra raises $21.5M

...raised $21.5 million in a series A round co-led by HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners...
BioCentury | Sep 27, 2007
Financial News

GlobeImmune raises $41.2 million

...Boston Life Science Venture Corp.; and WRF Capital joined existing investors HealthCare Ventures; Morgenthaler Ventures; Sequel Venture Partners...
BioCentury | Sep 19, 2005
Finance

Ebb & Flow

...round were Duquesne; Healthcare Investment Partners; MDS Capital; HealthCare Ventures; TPG Ventures; Morgenthaler Ventures; Perseus; Sequel Venture Partners...
BioCentury | Sep 15, 2005
Financial News

GlobeImmune raises $34.3 million

...Genentech (DNA); Partners Healthcare; and GC&H Investments joined existing investors HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners...
BioCentury | Sep 9, 2005
Financial News

Replidyne raises $62.5 million

...Healthcare Investment Partners; and MDS Capital. Existing investors HealthCare Ventures; TPG Ventures; Morgenthaler Ventures; Perseus; Sequel Venture Partners...
BioCentury | Oct 4, 2004
Finance

4Q Financial Markets Preview: Room to maneuver

...at $6.53. Investors included existing stockholders New Enterprise Associates; InterWest Partners; Perseus-Soros Biopharmaceutical Fund; and Sequel Venture Partners...
BioCentury | Sep 27, 2004
Financial News

Myogen raises $60 million

...1.8 million shares at $7.80 each. Investors included New Enterprise Associates; InterWest Partners; Perseus-Soros; and Sequel Venture Partners...
BioCentury | Aug 23, 2004
Finance

Follow the money

...TPG Ventures led the round. Other investors included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Morgenthaler; and Sequel Venture Partners...
BioCentury | Aug 17, 2004
Financial News

Replidyne raises $40 million

...investors in the infectious disease company included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners...
BioCentury | Sep 1, 2003
Finance

Ebb & Flow

...stockholders include New Enterprise Associates (28.5%); JPMorgan (20.4%); InterWest (13%); Perseus-Soros BioPharmaceutical Fund (8.1%); and Sequel Venture Partners...
Items per page:
1 - 10 of 13